Johanne A Windeløv1,2, Nicolai J Wewer Albrechtsen1,2,3,4, Rune E Kuhre1,2, Sara L Jepsen1,2, Daniel Hornburg4, Jens Pedersen1,2, Elisa P Jensen1,2, Katrine D Galsgaard1,2, Marie Winther-Sørensen1,2, Anne Ørgaard1,2, Carolyn F Deacon1,2, Matthias Mann3,4, Hannelouise Kissow1, Bolette Hartmann1,2, Jens J Holst5,6. 1. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. 2. NNF Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark. 4. Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany. 5. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. jjholst@sund.ku.dk. 6. NNF Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. jjholst@sund.ku.dk.
Abstract
AIMS/HYPOTHESIS: In humans, glucagon-like peptide-1 (GLP-1) is rapidly degraded by dipeptidyl peptidase-4 to a relatively stable metabolite, GLP-1(9-36)NH2, which allows measurement of GLP-1 secretion. However, little is known about the kinetics of the GLP-1 metabolite in mice. We hypothesised that the GLP-1 metabolite is rapidly degraded in this species by neutral endopeptidase(s) (NEP[s]). METHODS: We administered glucose, mixed meal or water orally to 256 mice, and took blood samples before and 2, 6, 10, 20, 30, 60 or 90 min after stimulation. To study the metabolism of the GLP-1 metabolite, i.v. GLP-1(9-36)NH2 (800 fmol) or saline (154 mmol/l NaCl) was administered to 160 mice, some of which had a prior injection of a selective NEP 24.11 ± inhibitor (candoxatril, 5 mg/kg) or saline. Blood was collected before and 1, 2, 4 and 12 min after GLP-1/saline injection. Plasma GLP-1 levels were analysed using a customised single-site C-terminal ELISA, two different two-site ELISAs and MS. RESULTS: GLP-1 secretion profiles after oral glucose administration differed markedly when assayed by C-terminal ELISA compared with sandwich ELISAs, with the former showing a far higher peak value and AUC. In mice injected with GLP-1(9-36)NH2, immunoreactive GLP-1 plasma levels peaked at approximately 75 pmol/l at 1 min when measured with sandwich ELISAs, returning to baseline (~20 pmol/l) after 12 min, but remained elevated using the C-terminal ELISA (~90 pmol/l at 12 min). NEP 24.11 inhibition by candoxatril significantly attenuated GLP-1(9-36)NH2 degradation in vivo and in vitro. MS identified GLP-1 fragments consistent with NEP 24.11 degradation. CONCLUSIONS/ INTERPRETATION: In mice, the GLP-1 metabolite is eliminated within a few minutes owing to endoproteolytic cleavage by NEP 24.11. Therefore, accurate measurement of GLP-1 secretion in mice requires assays for NEP 24.11 metabolites. Conventional sandwich ELISAs are inadequate because of endoproteolytic cleavage of the dipeptidyl peptidase-4-generated metabolite.
AIMS/HYPOTHESIS: In humans, glucagon-like peptide-1 (GLP-1) is rapidly degraded by dipeptidyl peptidase-4 to a relatively stable metabolite, GLP-1(9-36)NH2, which allows measurement of GLP-1 secretion. However, little is known about the kinetics of the GLP-1 metabolite in mice. We hypothesised that the GLP-1 metabolite is rapidly degraded in this species by neutral endopeptidase(s) (NEP[s]). METHODS: We administered glucose, mixed meal or water orally to 256 mice, and took blood samples before and 2, 6, 10, 20, 30, 60 or 90 min after stimulation. To study the metabolism of the GLP-1 metabolite, i.v. GLP-1(9-36)NH2 (800 fmol) or saline (154 mmol/l NaCl) was administered to 160 mice, some of which had a prior injection of a selective NEP 24.11 ± inhibitor (candoxatril, 5 mg/kg) or saline. Blood was collected before and 1, 2, 4 and 12 min after GLP-1/saline injection. Plasma GLP-1 levels were analysed using a customised single-site C-terminal ELISA, two different two-site ELISAs and MS. RESULTS:GLP-1 secretion profiles after oral glucose administration differed markedly when assayed by C-terminal ELISA compared with sandwich ELISAs, with the former showing a far higher peak value and AUC. In mice injected with GLP-1(9-36)NH2, immunoreactive GLP-1 plasma levels peaked at approximately 75 pmol/l at 1 min when measured with sandwich ELISAs, returning to baseline (~20 pmol/l) after 12 min, but remained elevated using the C-terminal ELISA (~90 pmol/l at 12 min). NEP 24.11 inhibition by candoxatril significantly attenuated GLP-1(9-36)NH2 degradation in vivo and in vitro. MS identified GLP-1 fragments consistent with NEP 24.11 degradation. CONCLUSIONS/ INTERPRETATION: In mice, the GLP-1 metabolite is eliminated within a few minutes owing to endoproteolytic cleavage by NEP 24.11. Therefore, accurate measurement of GLP-1 secretion in mice requires assays for NEP 24.11 metabolites. Conventional sandwich ELISAs are inadequate because of endoproteolytic cleavage of the dipeptidyl peptidase-4-generated metabolite.
Entities:
Keywords:
ELISA; GLP-1(9–36)NH2; Gut hormone; In vivo; Mice
Authors: D B Northridge; A G Jardine; C T Alabaster; P L Barclay; J M Connell; H J Dargie; S G Dilly; I N Findlay; A F Lever; G M Samuels Journal: Lancet Date: 1989-09-09 Impact factor: 79.321
Authors: M J Bak; N J Wewer Albrechtsen; J Pedersen; F K Knop; T Vilsbøll; N B Jørgensen; B Hartmann; C F Deacon; L O Dragsted; J J Holst Journal: Diabetes Obes Metab Date: 2014-07-22 Impact factor: 6.577
Authors: A Alamshah; A K McGavigan; E Spreckley; J S Kinsey-Jones; A Amin; I R Tough; H C O'Hara; A Moolla; K Banks; R France; G Hyberg; M Norton; W Cheong; A Lehmann; S R Bloom; H M Cox; K G Murphy Journal: Diabetes Obes Metab Date: 2016-04-01 Impact factor: 6.577
Authors: T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp Journal: Mol Metab Date: 2019-09-30 Impact factor: 7.422
Authors: Nathalie Esser; Stephen M Mongovin; Jacqueline Parilla; Breanne M Barrow; Thomas O Mundinger; Brendy S Fountaine; Megan J Larmore; Joseph J Castillo; Rehana Akter; Rebecca L Hull; Sakeneh Zraika Journal: Am J Physiol Endocrinol Metab Date: 2022-02-07 Impact factor: 4.310
Authors: Nathalie Esser; Christine Schmidt; Breanne M Barrow; Laura Cronic; Daryl J Hackney; Stephen M Mongovin; Meghan F Hogan; Andrew T Templin; Joseph J Castillo; Rebecca L Hull; Sakeneh Zraika Journal: Front Endocrinol (Lausanne) Date: 2022-06-06 Impact factor: 6.055
Authors: Qinghe Meng; Oleg G Chepurny; Colin A Leech; Napat Pruekprasert; Megan E Molnar; James Jason Collier; Robert N Cooney; George G Holz Journal: Diabetes Obes Metab Date: 2022-04-07 Impact factor: 6.408
Authors: Benedikt A Aulinger; Marta Perabo; Randy J Seeley; Klaus G Parhofer; David A D'Alessio Journal: Am J Physiol Endocrinol Metab Date: 2019-11-19 Impact factor: 4.310